

# LUND UNIVERSITY

### Mechanisms for Targeting of Proteins to Secretory Lysosomes of Haematopoietic Cells

Rosén, Hanna

2006

### Link to publication

*Citation for published version (APA):* Rosén, H. (2006). *Mechanisms for Targeting of Proteins to Secretory Lysosomes of Haematopoietic Cells.* [Doctoral Thesis (compilation), Division of Hematology and Transfusion Medicine]. Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University.

Total number of authors:

#### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors

and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study

or research.

You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

**PO Box 117** 221 00 Lund +46 46-222 00 00





Available online at www.sciencedirect.com



Biochemical and Biophysical Research Communications 315 (2004) 671-678

www.elsevier.com/locate/ybbrc

# Sorting of Von Willebrand factor to lysosome-related granules of haematopoietic cells

Hanna Rosén,<sup>a</sup> Jero Calafat,<sup>b</sup> Lars Holmberg,<sup>c</sup> and Inge Olsson<sup>a,\*</sup>

<sup>a</sup> Department of Hematology, C14, BMC, S-221 84 Lund, Sweden <sup>b</sup> The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands <sup>c</sup> Department of Paediatrics, C14, BMC, S-221 84 Lund, Sweden

Received 19 December 2003

#### Abstract

The aim of this work was to investigate sorting mechanisms of von Willebrand factor (VWF) when expressed in haematopoietic cells. The processing and sorting of both the wild-type VWF and a multimerization defective propeptide-mutant (VWF<sub>m</sub>) were investigated after expression in the 32D cell line. Normal proteolytic processing was observed for both proteins, however the processing of VWF<sub>m</sub> was much slower and a large portion was unprocessed. Results from subcellular fractionation and immunoelectron microscopy confirmed that a part of VWF, but not VWF<sub>m</sub>, was targeted to lysosome-related granules. Partial constitutive secretion was also observed for all forms of VWF and VWF<sub>m</sub>. Inhibition of acidification by chloroquine blocked VWF processing but allowed unprocessed pro-VWF targeting to dense organelles. In conclusion, our observations are consistent with VWF multimerization being of importance in cellular retention and targeting to lysosome-related organelles in haematopoietic cells, suggesting a role of protein aggregation for sorting in these cells. © 2004 Elsevier Inc. All rights reserved.

Keywords: Multimerization; Aggregation; Targeting; Secretory lysosome; Basophil

The von Willebrand factor (VWF) has an important role in hemostasis by mediating platelet adhesion to the injured subendothelium and by its function as a carrier protein in the protection of coagulation factor VIII. VWF is normally stored in the Weibel-Palade bodies of endothelial cells [1] and in platelet granules [2]. After endothelial cell biosynthesis, the VWF undergoes a series of processing steps including C-terminal dimerization, glycosylation, sulphation, N-terminal multimerization, and propeptide removal to finally becoming sorted for storage or secreted as high molecular weight multimers [3,4]. Furthermore, VWF can redirect coagulation factor VIII from a constitutive to a regulated secretory pathway by a chaperone-like mechanism [5]. VWF can also form storage granules when expressed in cells other than endothelial cells and megakaryocytes [6]. To determine the sorting role of multimerization, we

have chosen to investigate the fate of VWF when constitutively expressed as an exogenous protein in haematopoietic cells.

Haematopoietic cells manufacture lysosome-related organelles [7] such as the azurophil granules of the neutrophil series that lack the lysosome-associated membrane proteins LAMP-1 and LAMP-2 [8,9] but carry the membrane protein CD63/LAMP-3 [10,11]. Sorting mechanisms are not unique for endogenous proteins in these cells inasmuch as gene transfected nonhaematopoietic proteins may also be sorted for granule storage [12,13]. Protein aggregation has been suggested to play a role in secretory granule sorting in endocrine and neuroendocrine cells [14,15]. As the itinerary for retrieval may be dependent on protein self-association and aggregation, results from the naturally self-associating VWF could shed light on principles for cellular retrieval and sorting in haematopoietic cells. Stable expression of VWF cDNA constructs was assumed to result in the synthesis and translocation of the protein into the lumen of the ER and followed, after quality

<sup>\*</sup>Corresponding author. Fax: +46-46-184493. *E-mail address:* Inge.Olsson@hematologi.lu.se (I. Olsson).

<sup>0006-291</sup>X/\$ - see front matter © 2004 Elsevier Inc. All rights reserved. doi:10.1016/j.bbrc.2004.01.106

control, by export of normally folded protein to the Golgi complex. The protein may then undergo either constitutive secretion or lysosome-related organelle targeting.

The role of multimerization in sorting might be illustrated with a multimerization defective VWF mutant (VWF<sub>m</sub>) [16]. We therefore asked whether both VWF and VWF<sub>m</sub> could be targeted to lysosome-related organelles when constitutively expressed in haematopoietic cells such as the murine myeloblast-like 32D cell line [17].

#### Materials and methods

Cell culture. Murine myeloblast-like 32D c13 cells [17] were grown in Iscove's modified Dulbecco's medium (Gibco) with glutamax or IMDM with L-glutamine supplemented with 10% FBS (Gibco). WEHI-conditioned medium (30%) was added as a source of interleukin-3 [18].

cDNA expression. Inserts of cDNA encoding VWF and VWF<sub>m</sub> [16] were excised from pSVH-VWF and pMT2-VWF<sub>m</sub> followed by ligation into pcDNA3.1(+) (Invitrogen) to create the expression vectors pcDNA3-VWF and -VWF<sub>m</sub>. The 32D cells were transfected (Genepulser II, BioRad) with electrical settings of 960 µF and 260 V after addition of 15 µg plasmid to 4 × 10<sup>6</sup> cells in 400 µl complete medium. After electroporation, 5 × 10<sup>5</sup> cells/ml were incubated for 48 h to allow expression of the geneticin resistance. A maximum of 5000 cells per well were then seeded in 100 µl complete medium with 1 mg/ml geneticin in 96-well plates. The multimeric structure of the expressed VWF was determined by electrophoresis in 1.1% agarose under nonreducing conditions [16]. The proteins were blotted onto Hybond PVDF membranes, that were incubated with the monoclonal VWF antibody M616 (DAKO), and the Alkaline Phosphatase substrate rabbit anti-mouse DO314 (DAKO).

Biosynthetic radiolabelling, immunoprecipitation, and subcellular fractionation were performed as previously described [19]. SDS– PAGE was performed in a precast 4–12% Tris–glycine gel (Novex). The peak activity of  $\beta$ -hexosaminidase and galactosyl transferase in subcellular Percoll fractions of 32D c13 cells was localized in fractions 2 and 6, respectively [13]. Polyclonal antibodies against human VWF (A0082) (DAKO A/S) and monoclonal antiserum against the propeptide of human VWF (BR5 and 8H10) from Dr. Ulrich Vischer were used.

Immunoelectron microscopy. 32D cells stably transfected with VWF or with VWFm were fixed for 24 h in 2% paraformaldehyde in 0.1 M PHEM buffer (60 mM PIPES, 25 mM Hepes, 2 mM MgCl<sub>2</sub>, and 10 mM EGTA, pH 6.9) and then processed for ultrathin cryosectioning as previously described [20]. 45-nm cryosections were cut at -120 °C using diamond knives (Drukker Cuijk, The Netherlands) in an ultracryomicrotome (Leica Aktiengesellschaft, Vienna, Austria) and transferred with a mixture of sucrose and methylcellulose onto formvar-coated copper grids [21]. The grids were placed on 35-mm petri dishes containing 2% gelatine. For double immunolabelling the pro-cedure described by Slot et al. [22] was followed with 10- and 15-nm protein-A conjugated colloidal gold probes (EM Lab., Utrecht University, The Netherlands). The antibodies used were a rat monoclonal ID4B against mouse LAMP-1 (CD107a) (Pharmingen Leiden, The Netherlands) and a rabbit anti-VWF. After immunolabelling, the cryosections were embedded in a mixture of methylcellulose and uranyl acetate and examined using a Philips CM 10 electron microscope (Eindhoven, The Netherlands). For the controls, the primary antibody was replaced by the corresponding non-relevant rat and rabbit antiserum.

#### Results

#### Von Willebrand factor processing and secretion

Results from agarose electrophoresis under non-reducing conditions showed multimer formation of VWF, whereas no aggregates larger than the protomer were observed for  $VWF_m$  (Fig. 1).

Biosynthetic pulse-chase radiolabelling was used to investigate VWF processing. Immunoprecipitation was performed with two different antibodies, one that reacts with both the pro-VWF and mature VWF (anti-VWF), and another that reacts with pro-VWF and released VWF propeptide but not the mature VWF (anti-pro-VWF). Immunoprecipitation with anti-VWF of 1h pulse cell lysates showed a major band corresponding to pro-VWF (Fig. 2A). During the radiolabel chase mature VWF was also observed. In addition, secreted mature VWF was observed, but secreted pro-VWF was barely detectable (Fig. 2A). However, the results from immunoprecipitation with anti-pro-VWF confirmed that pro-VWF was also secreted (Fig. 3A). Densitometric analyses after 1 and 3 h of radiolabel chase showed the ratio between the cellular pro-VWF and mature VWF to be 1.3 and 1.1, respectively (data not shown). This indicates that more than half of the pro-VWF produced was processed to mature VWF. Furthermore, the ratio between intra- and extra-cellular mature VWF was 13.5 and 1.8 at the same time points. As extracellular VWF increased even further with time, approximately half the mature VWF generated was estimated to be constitutively secreted. Thus, half of the VWF generated was retained and half secreted. The propeptide released during radiolabel chase was present in both the cells and the medium (Fig. 3A). Densitometric data from the radiolabel chase revealed the ratio between intra- and extra-cellular propeptide to be 3.4 and 2.4 at 1 and 3 h,



Fig. 1. Multimer analysis of VWF and VWF<sub>m</sub>. Medium from 32D cells transfected with cDNA for wild-type VWF and VWF<sub>m</sub> with a mutation in the propeptide was analysed by electrophoresis in 1.1% agarose under non-reducing conditions. A range of multimers are seen with VWF, but only the fastest moving band (the protomer) with VWF<sub>m</sub>. The control to the left consists of VWF multimers from normal plasma (NP).





Fig. 2. Processing of wild-type VWF and mutated VWF<sub>m</sub> as detected with an antibody against VWF. 32D cells transfected with cDNA for wild-type VWF (A) and VWF<sub>m</sub> with a mutation in the propeptide (B) were radiolabelled with 25  $\mu$ Ci/mL [<sup>35</sup>S]methionize/[<sup>35</sup>S]cysteine for 1 h followed by chase of the radiolabel for up to 20h. At depicted time points, 20 × 10<sup>6</sup> cells and medium were removed, immunoprecipitated with anti-VWF, and analysed by SDS-PAGE. The fluorogram of medium in B was overexposed to increase the visibility of the secreted forms. The positions of pro-VWF, VWF, pro-VWF<sub>m</sub>, and VWF<sub>m</sub> are indicated to the right with arrows.



Fig. 3. Processing of wild-type VWF and VWF<sub>m</sub> as detected with an antibody against the VWF propeptide. 32D cells transfected with VWF (A) and VWF<sub>m</sub> (B) cDNA were radiolabelled with 25 µCi/mL [<sup>35</sup>S]methionine/[<sup>35</sup>S]cysteine for 1 h followed by chase of the radiolabel for up to 20 h. At depicted time points, 20 × 10<sup>6</sup> cells and medium were removed, immunoprecipitated with antibodies against the VWF propeptide, and analysed by SDS–PAGE. The positions of pro-VWF, the propeptide, pro-VWF<sub>m</sub>, and the mutated propeptide (propeptide<sub>m</sub>) are indicated to the right with arrows. Numbers to the left are the values of molecular mass standards.

respectively (data not shown). Again, an additional increase in the extracellular propeptide with time was noticed (Fig. 3A), indicating that approximately half the generated propeptide was secreted. Thus, cellular retention and constitutive secretion appeared to be similar for both the mature VWF and the released propeptide. The processing of  $VWF_m$  was slower than that of VWF. Mature VWF<sub>m</sub> was first observed in the cell lysates after 3h of radiolabel chase (Fig. 2B). Both pro-VWF\_m and VWF<sub>m</sub> were secreted during radiolabel chase (Figs. 2B and 3B). Cleaved mutated propeptide was also secreted in a similar manner to the wild-type (Fig. 3B). Densitometric analyses of data from Fig. 3B indicated that all the released propeptide was secreted (data not shown), consistent with a lack of propeptide targeting to lysosome-related organelles.

#### Von Willebrand factor targeting

The VWF propeptide is known to be involved in the multimerization process [23,24]. We therefore investigated whether the targeting to lysosome-related organelles was similar for VWF and multimerization defective



Fig. 4. Subcellular targeting of wild-type VWF and mutated VWF<sub>m</sub> as detected with an antibody against VWF. 32D cells transfected with VWF (A) and VWF<sub>m</sub> (B) cDNA were radiolabelled with 25 µCi/mL [<sup>35</sup>S]methionine/<sup>155</sup>S[cysteine for 30min followed by chase of the radiolabel for 3 h. At these time points, 100 × 10<sup>6</sup> cells were subcellular fractionated on a Percoll gradient [19]. The fractions were immuno-precipitated with anti-VWF and analysed by SDS-PAGE. The positions of pro-VWF, VWF, and pro-VWF<sub>m</sub> are indicated to the right with arrows. The peak activity of β-hexosaminidase (lysosome-related organelles) and galactosyl transferase (Golgi) was localized in fractions 2 and 6, respectively [13]. Numbers to the left are the values of molecular mass standards.



Fig. 5. Subcellular targeting of wild-type VWF and VWF<sub>m</sub> as detected with an antibody against the VWF propeptide. 32D cells transfected with VWF (A) and VWF<sub>m</sub> (B) cDNA were radiolabelled with  $25 \,\mu$ Ci/mL [<sup>35</sup>S]methionine[<sup>35</sup>S]cysteine for 30 min followed by chase of the radiolabel for 3 h. At these time points,  $100 \times 10^6$  cells were subcellular fractionated on a Percoll gradient [19]. The fractions were immunoprecipitated with antibodies against the VWF propeptide and analysed by SDS–PAGE. The positions of pro-VWF, the propeptide, and pro-VWF<sub>m</sub> are indicated to the right with arrows. The peak activity of β-hexosaminidase (lysosome-related organelles) and galactosyl transferase (Golgi) was localized in fractions 2 and 6, respectively [13]. Numbers to the left are the values of molecular mass standards.

VWF<sub>m</sub>. The cells were subcellularly fractionated after 30 min radiolabelling and 3 h subsequent radiolabel chase. Proteins were immunoprecipitated with anti-VWF (Fig. 4) or anti-pro-VWF (Fig. 5). After 30 min, radiolabelled pro-VWF was concentrated into fractions corresponding to ER and Golgi elements (Fig. 4A). Upon radiolabel chase, a slight accumulation of mature vWF was observed in the densest granule-containing fractions (Fig. 4A). The finding that VWF was present in all fractions after the radiolabel chase implied that pro-VWF cleavage to generate VWF occurred in nongranule organelles, presumably in the TGN [3]. Furthermore, the data suggested that a portion of the released propeptide was transported to the densest organelles (Fig. 5A) while another portion was constitutively secreted as seen in Fig. 3. The relative distribution of VWF (Fig. 4A) and released propeptide (Fig. 5A) in the subcellular fractions was compared by densitometry after 3h radiolabel chase. The data showed a similar distribution for both VWF and free propeptide (not shown).

Subcellular fractionation experiments of radiolabelled cells showed pro-VWF<sub>m</sub> in most subcellular fractions without accumulation in the densest organelles upon radiolabel chase (Figs. 4B and 5B). Cleaved, mutated propeptide was not observed, a finding that could be explained by the slow processing with only a minor release of mutated propeptide during a 3-h experiment (see Fig. 3B). Thus, our results are consistent with slow export of VWF<sub>m</sub> from the ER and subsequent constitutive secretion and inability to target lysosome-related organelles. If granule targeting requires aggregate for-

mation, the lack of multimer formation may have prevented this targeting and resulted in constitutive secretion by default.

Results from immunoelectron microscopy using double immunogold labelling in 32D cells transfected with VWF revealed colocalization between VWF and the lysosomal marker LAMP-1 [25,26] (Fig. 6A). Aggregate-like VWF labelling was associated with the lumen of multivesicular bodies corresponding to the lysosome-related organelles of the cells, indicating that some VWF was targeted to these organelles. On the other hand, VWF<sub>m</sub> was not identified in the multivesicular bodies/granules of cells transfected with the gene for this protein (Figs. 6B-D). However, clusters of the gene product were observed to some extent in swollen ER (Figs. 6C and D). Unsuccessful efforts were made to detect pro-VWF in lysosome-related organelles using anti-pro-VWF (data not shown). In conclusion, VWF but not VWF<sub>m</sub> was targeted to lysosome-related organelles of 32D cells.

#### Von Willebrand factor turnover

Both pro-VWF and VWF were degraded during radiolabel chase (Fig. 7A). When organelle acidification was blocked with chloroquine, two effects were observed. First, chloroquine inhibited the processing of pro-VWF into VWF, indicating pH-dependency for this step (Fig. 7A). Second, chloroquine inhibited the degradation of pro-VWF (Fig. 7A). The amount of secreted protein was unaffected by chloroquine although secreted pro-VWF predominated (Fig. 7A). In contrast, chloroquine

H. Rosén et al. | Biochemical and Biophysical Research Communications 315 (2004) 671-678



Fig. 6. Intracellular localization of wild-type and mutated von Willebrand factor. Ultrathin cryosections from 32D cells transfected with VWF (A) and VWF<sub>m</sub> (B–D) were double labelled in (A) with rabbit anti-VWF followed by protein A gold (10 nm) and rat anti-LAMP-1, followed by rabbit anti-rat IgG and protein A gold (15 nm); in (B–D) cells were labelled with rabbit anti-VWF and protein A gold (10 nm). In (A), an area of a cell is shown with a large multivesicular body/granule (g) double labelled with LAMP-1 (15 nm-gold) on the membrane and VWF (10 nm-gold) in the lumen, mainly in a large aggregate; some labelling is present in the endoplasmic reticulum (er). (B) Large area of a cell at low magnification showing labelling for VWF<sub>m</sub> in the endoplasmic reticulum (er) and no labelling in the multivesicular bodies/granules (g). Nucleus (n). (C,D) Higher magnification of areas from other cells showing swollen endoplasmic reticulum (er) containing VWF<sub>m</sub> protein arranged in clusters. Bars, 200 nm.

did not affect the degradation of pro-VWF<sub>m</sub> during radiolabel chase (Fig. 7B). However, mature VWF<sub>m</sub> was not observed, suggesting that chloroquine inhibited its production (Fig. 7B).

The subcellular distribution of radiolabelled pro-VWF was not affected by chloroquine (Fig. 7C). The processing inhibition was not complete in this experiment because the chloroquine was added after pulse radiolabelling (Fig. 7C), but complete processing inhibition was observed when chloroquine was present during the whole experiment (Fig. 7B). Even if the VWF formation was blocked, the subcellular distribution of pro-VWF was similar in the presence or absence of chloroquine. This suggested that the pro-VWF accumulation in the densest fractions corresponding to the lysosome-related organelles might occur without a requirement for acidification and VWF formation.

The VWF and VWF<sub>m</sub> stability was not affected by  $10 \,\mu M$  of the proteasomal inhibitor lactacystin, suggesting the degradation of these proteins not to involve the proteasome (data not shown).

#### Discussion

Expression of VWF cDNA has been achieved previously in non-endothelial cell types [6,24,27–30], and now in the present work with haematopoietic cells. VWFcontaining granules have been observed after VWF cDNA expression in endocrine and neuroendocrine cells



The horosoft were and VWF<sub>m</sub> 32D cells transfected with VWF (A) and VWF<sub>m</sub> (B) were incubated with 25 μCi/mL [<sup>35</sup>S]methionine/ [<sup>35</sup>S]cysteine for 1 h, followed by chase of the radiolabel for up to 16 h without (control) or with 100 μM chloroquine. At depicted time points, 20 × 10<sup>6</sup> cells and medium were removed, immunoprecipitated with anti-VWF, and analysed by SDS–PAGE. The positions of pro-VWF, VWF, pro-VWF<sub>m</sub>, and VWF<sub>m</sub> are indicated to the right with arrows. (C) Cells transfected with VWF cDNA were radiolabelled with [<sup>35</sup>S]methionine[<sup>35</sup>S]cysteine for 30min followed by chase of the radiolabel for 3 h without (control) or with 100 µM chloroquine, after which 100 × 10<sup>6</sup> cells were subjected to subcellular fractionation on a Percoll gradient [19]. The fractions were immunoprecipitated with anti-VWF and analysed by SDS–PAGE. The positions of pro-VWF, VWF, pro-VWF<sub>m</sub>, and VWF<sub>m</sub> are indicated to the right with arrows. The peak activity of β-hexosaminidase (lysosome-related organelles) and galactosyl transferase (Golgi) was localized in fractions 2 and 6, respectively [13].

[6], as well as in monkey kidney CV-1 cells [31]. VWF multimer assembly is a prerequisite for dense-core organelle biogenesis in endothelial cells [4], but not a general requirement for VWF granule targeting since targeting was observed in AtT-20 cells of a VWF variant with almost complete loss of N-terminal multimerization [32]. Most of the VWF was processed intracellularly, but some pro-VWF was secreted unprocessed indicating it had not undergone cleavage. However, much more VWF than pro-VWF was secreted. The correlation between processing and secretion indicated that furin-catalysed cleavage of the propeptide was followed by secretion of both the mature VWF and the propeptide, similar to that seen in endothelial cells [3,33]. The rate of secretion of pro-VWF<sub>m</sub>, mature VWF<sub>m</sub>, and released mutant propeptide was also slower. The furin-cleavage site is not affected in the VWF<sub>m</sub> and the portion of the protein that escaped ER retention and degradation was obviously secreted. Thus, multimer assembly was not necessary for constitutive secretion.

The conclusion that VWF is targeted to lysosomerelated organelles was based on the assumption that subcellular fractionation detected a shift in density as these organelles were formed. However, this density shift is not always easily detectable since the organelles may have a wide density distribution. Therefore, immunoelectron microscopy data were used to substantiate the evidence for lysosome-related VWF organelle targeting and lack of  $\ensuremath{VWF_m}$  targeting. A major question addressed in this paper was whether multimerization/ aggregation played a role in lysosome-related organelle sorting. Aggregation is thought to be an important step in protein sorting to regulated secretory granules of endocrine cells [14,34]. In the latter, proteins are routed to vesicles within the TGN (sorting-for-entry) whereupon processing and segregation is completed in the mature granules (sorting-for-retention) [35,36]. VWF targeting into Weibel-Palade bodies has been postulated to depend on VWF multimerization [31], and VWFcontaining granules seem to form only in cells that synthesize polymerized VWF [37]. Therefore, it is possible that VWF multimerization is also important in sorting-for-entry to lysosome-related organelles of haematopoietic cells when expressing VWF. However, dimeric VWF can also be targeted to storage organelles [6,38], indicating multimerization not to be necessary for targeting. A similar relative distribution of both mature VWF and released propeptide in the subcellular fractions suggested that propeptide could be non-covalently associated with VWF after cleavage. Propeptide has been shown to bind to mature VWF [3] and suggested to navigate sorting-for-entry by non-covalent association with VWF in AtT-20 cells [32]. Some cells may therefore possess targeting receptors or chaperone proteins that direct VWF to storage compartments, and sorting mechanisms might be cell-type specific.

The lack of lysosome-related organelle targeting of the multimerization-defective VWF<sub>m</sub> mutant, in contrast to wild-type VWF, may also support a role for protein self-association in sorting. Even if pro-VWF<sub>m</sub> was processed to generate both the mature VWF and the mutated propeptide forms, pro-VWF<sub>m</sub>-derived VWF was not detectable in lysosome-related organelles of 32D cells. Furthermore, in contrast to non-mutated propeptide, all released mutated propeptide was constitutively secreted (Fig. 3B). It should be noted that the processing

of pro-VWF<sub>m</sub> was slower than for wild-type pro-VWF, probably as a result of abnormal folding that slows ERexport. As the furin cleavage site is intact in pro-VWF<sub>m</sub>, this rules out defective cleavage to be the problem. Intact propeptide, necessary for multimer assembly, might be a prerequisite for VWF targeting and storage in the lysosome-related organelles. The uncleaved VWF propeptide may function as an intramolecular chaperone during the final folding prior to multimerization [32].

In conclusion, our observations are consistent with VWF multimerization being of importance in cellular retention and sorting-for-entry to lysosome-related organelles of haematopoietic cells. The results also suggested that VWF<sub>m</sub> may be prevented from targeting because of improper folding and therefore become constitutively secreted. The role for multimerization/aggregation in protein sorting is supported by the lack of multimerization of VWF<sub>m</sub> in vivo in patients with a variant of von Willebrand's disease [39] and when expressed in COS-7 cells [16].

#### Acknowledgments

This work was supported by the Swedish Cancer Foundation, the Swedish Foundation for Paediatric Cancer, the Alfred Österlund Foundation, and funds from the Lund University Hospital. We are grateful to Ann-Charlotte Kristoffersson for technical assistance.

#### References

- [1] E.R. Weibel, G.E. Palade, New cytoplasmic components in arterial endothelia, J. Cell Biol. 23 (1964) 101-112.
- [2] H.R. Gralnick et al., Platelet von Willebrand factor, Mayo Clin. Proc. 66 (6) (1991) 634–640.
- [3] U.M. Vischer, D.D. Wagner, von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies, Blood 83 (12) (1994) 3536–3544.
- [4] T.R. de Wit, J.A. van Mourik, Biosynthesis, processing and secretion of von Willebrand factor: biological implications, Best Pract. Res. Clin. Haematol. 14 (2) (2001) 241–255.
- [5] J.B. Rosenberg et al., Intracellular trafficking of factor VIII to von Willebrand factor storage granules, J. Clin. Invest. 101 (3) (1998) 613–624.
- [6] D.D. Wagner et al., Induction of specific storage organelles by von Willebrand factor propolypeptide, Cell 64 (2) (1991) 403–413.
  [7] U. Gullberg et al., Processing and targeting of granule proteins in
- [7] U. Gullberg et al., Processing and targeting of granule proteins in human neutrophils, J. Immunol. Methods 232 (1–2) (1999) 201– 210.
- [8] C. Dahlgren et al., The lysosomal membrane glycoproteins Lamp-I and Lamp-2 are present in mobilizable organelles, but are absent from the azurophil granules of human neutrophils, Biochem. J. 311 (Pt. 2) (1995) 667–674.
- [9] A.M. Cieutat et al., Azurophilic granules of human neutrophilic leukocytes are deficient in lysosome-associated membrane proteins but retain the mannose 6-phosphate recognition marker, Blood 91 (3) (1998) 1044–1058.
- [10] B.P. Cham, J.M. Gerrard, D.F. Bainton, Granulophysin is located in the membrane of azurophilic granules in human neutrophils and mobilizes to the plasma membrane following cell stimulation, Am. J. Pathol. 144 (6) (1994) 1369–1380.

- H.T. Maecker, S.C. Todd, S. Levy, The tetraspanin superfamily: molecular facilitators, FASEB J. 11 (6) (1997) 428-442.
   E. Bulow, U. Gullberg, I. Olsson, Structural requirements for
- [12] E. Bulow, U. Gullberg, I. Olsson, Structural requirements for intracellular processing and sorting of bactericidal/permeabilityincreasing protein (BPI): comparison with lipopolysaccharidebinding protein, J. Leukoc. Biol. 68 (5) (2000) 669–678.
- E. Bulow et al., Sorting for storage in myeloid cells of nonmyeloid proteins and chimeras with the propertide of myeloperoxidase precursor, J. Leukoc. Biol. 71 (2) (2002) 279–288.
   S.A. Tooze, G.J. Martens, W.B. Huttner, Secretory granule
- [14] S.A. Tooze, G.J. Martens, W.B. Huttner, Secretory granule biogenesis: rafting to the SNARE, Trends Cell Biol. 11 (3) (2001) 116–122.
- [15] H.H. Gerdes et al., The primary structure of human secretogranin II, a widespread tyrosine-sulfated secretory granule protein that exhibits low pH- and calcium-induced aggregation, J. Biol. Chem. 264 (20) (1989) 12009–12015.
- [16] L. Holmberg et al., Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand's disease, Thromb. Haemost. 79 (4) (1998) 718–722.
- [17] L. Liu, A. Oren, T. Ganz, Murine 32D c13 cells—a transfectable model of phagocyte granule formation, J. Immunol. Methods 181 (2) (1995) 253–258.
- [18] B.L. Kreider et al., Induction of the granulocyte-macrophage colony-stimulating factor (CSF) receptor by granulocyte CSF increases the differentiative options of a murine hematopoietic progenitor cell, Mol. Cell. Biol. 10 (9) (1990) 4846–4853.
- [19] H. Rosen et al., Artificially controlled aggregation of proteins and targeting in hematopoietic cells, J. Leukoc. Biol. 74 (5) (2003) 800– 809.
- [20] J. Calafat et al., Human monocytes and neutrophils store transforming growth factor-alpha in a subpopulation of cytoplasmic granules, Blood 90 (3) (1997) 1255–1266.
- [21] W. Liou, H.J. Geuze, J.W. Slot, Improving structural integrity of cryosections for immunogold labeling, Histochem. Cell Biol. 106 (1) (1996) 41-58.
- [22] J.W. Slot et al., Immuno-localization of the insulin regulatable glucose transporter in brown adipose tissue of the rat, J. Cell Biol. 113 (1) (1991) 123–135.
- [23] T.N. Mayadas, D.D. Wagner, In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls, J. Biol. Chem. 264 (23) (1989) 13497–13503.
- [24] C.L. Verweij, M. Hart, H. Pannekoek, Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation, EMBO J. 6 (10) (1987) 2885–2890.
- [25] J.W. Chen et al., Identification of two lysosomal membrane glycoproteins, J. Cell Biol. 101 (1) (1985) 85–95.
- [26] S.M. Mane et al., Purification and characterization of human lysosomal membrane glycoproteins, Arch. Biochem. Biophys. 268 (1) (1989) 360–378.
- [27] P.A. Kroner et al., Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease, J. Biol. Chem. 266 (29) (1991) 19146–19149.
- [28] R.J. Kaufman et al., Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells, Mol. Cell. Biol. 9 (3) (1989) 1233–1242.
- [29] J.C. Eikenboom et al., Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 88 (7) (1996) 2433–2441.
- [30] P. Meulien et al., Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector, Thromb. Haemost. 67 (1) (1992) 154–160.
- [31] J. Voorberg et al., Biogenesis of von Willebrand factor-containing organelles in heterologous transfected CV-1 cells, EMBO J. 12 (2) (1993) 749–758.

- [32] J.B. Rosenberg et al., The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF, Blood 100 (5) (2002) 1699–1706.
- [33] A. Borchiellini et al., Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-p-aprine vasopressin in humans, Blood 88 (8) (1996) 2951–2958.
- [34] P. Arvan, D. Castle, Sorting and storage during secretory granule biogenesis: looking backward and looking forward, Biochem. J. 332 (Pt. 3) (1998) 593-610.
- [35] P.S. Dannies, Protein hormone storage in secretory granules: mechanisms for concentration and sorting, Endocr. Rev. 20 (1) (1999) 3–21.
- [36] P.S. Dannies, Concentrating hormones into secretory granules: layers of control, Mol. Cell Endocrinol. 177 (1-2) (2001) 87-93.
- [37] J.A. van Mourik, T. Romani de Wit, J. Voorberg, Biogenesis and exocytosis of Weibel–Palade bodies, Histochem. Cell Biol. 117 (2) (2002) 113–122.
- [38] T.N. Mayadas, D.D. Wagner, Vicinal cysteines in the prosequence
- [38] T.N. Mayadas, D.D. Wagner, Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly, Proc. Natl. Acad. Sci. USA 89 (8) (1992) 3531–3535.
  [39] Z.M. Ruggeri et al., Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC), J. Clin. Invest. 70 (5) (1982) 1124–1127.